Graybug Vision Inc. (GRAY) NASDAQ

$2.70 -0.09 (-3.23%)

Market Cap: $57.56M

As of 11/26/21 01:00 PM EST. Market closed.

(GRAY)

Graybug Vision Inc. (GRAY) NASDAQ

$2.70 -0.09 (-3.23%)

Market Cap: $57.56M

As of 11/26/21 01:00 PM EST. Market closed.

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately ... read more

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a microparticle depot formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
31
Address
.
KEY STATS
Open
$2.70
Previous Close
$2.79
Days Range
$2.60 - $2.77
52 week range
$2.60 - $35.18
Volume
65,776
Avg. Volume (30 days)
199,031
Market Cap
$57.56M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
21,319,635
Open
$2.70
Previous Close
$2.79
Days Range
$2.60 - $2.77
52 week range
$2.60 - $35.18
Volume
65,776
Avg. Volume (30 days)
199,031
Market Cap
$57.56M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
21,319,635

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR GRAYBUG VISION INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
BREUIL ROBERT S Chief Financial Officer Sep 22, 2021 Sale $3.55 7,283 25,854 12,717 Sep 24, 2021, 07:16 PM
Clarus Lifesciences III, L.P. 10% Owner Sep 29, 2020 Buy $16.00 250,000 4,000,000 1,930,395 Oct 01, 2020, 06:30 PM
Flynn James E 10% Owner Sep 29, 2020 Buy $16.00 1,562,500 25,000,000 1,853,967 Oct 01, 2020, 05:36 PM
SHAFFER CHRISTY L Director Sep 29, 2020 Buy $16.00 18,750 300,000 1,605,240 Sep 29, 2020, 04:42 PM
ORBIMED ADVISORS LLC 10% Owner Sep 25, 2020 Buy $16.00 562,500 9,000,000 562,500 Sep 29, 2020, 04:41 PM
Buy Sale Option Exercise
Owner Relationship Date Value($)
BREUIL ROBERT S Chief Financial Officer 09/22/2021 25,854
Clarus Lifesciences III, L.P. 10% Owner 09/29/2020 4,000,000
Flynn James E 10% Owner 09/29/2020 25,000,000
SHAFFER CHRISTY L Director 09/29/2020 300,000
ORBIMED ADVISORS LLC 10% Owner 09/25/2020 9,000,000
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2021
03/31/2021
0.63%
2Q

Period of Report: 09/30/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2021
0.63%
2Q